Immunocore (NASDAQ:IMCR) Rating Reiterated by Guggenheim

Immunocore (NASDAQ:IMCR)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a research report issued on Tuesday, Benzinga reports. They presently have a $92.00 price objective on the stock. Guggenheim’s target price indicates a potential upside of 57.35% from the stock’s current price.

Several other research firms also recently commented on IMCR. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Immunocore in a research note on Wednesday, March 6th. Needham & Company LLC reissued a “buy” rating and set a $81.00 target price on shares of Immunocore in a research note on Thursday, April 11th. JPMorgan Chase & Co. lifted their target price on Immunocore from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Wednesday, March 20th. Canaccord Genuity Group lifted their target price on Immunocore from $60.00 to $63.00 and gave the company a “hold” rating in a research note on Thursday, February 29th. Finally, Oppenheimer reissued an “outperform” rating and set a $87.00 target price (up previously from $85.00) on shares of Immunocore in a research note on Thursday, February 29th. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $81.50.

Immunocore Stock Up 2.0 %

NASDAQ IMCR opened at $58.47 on Tuesday. The stock’s 50-day moving average price is $62.82 and its 200-day moving average price is $60.59. The company has a quick ratio of 3.77, a current ratio of 3.80 and a debt-to-equity ratio of 0.13. Immunocore has a 52 week low of $42.21 and a 52 week high of $76.98. The company has a market capitalization of $2.91 billion, a P/E ratio of -50.40 and a beta of 0.89.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.12). Immunocore had a negative return on equity of 15.78% and a negative net margin of 22.48%. The company had revenue of $70.16 million during the quarter, compared to the consensus estimate of $53.25 million. During the same period last year, the business earned ($0.63) EPS. The firm’s quarterly revenue was up 22.4% compared to the same quarter last year. On average, equities research analysts predict that Immunocore will post -1.54 earnings per share for the current year.

Hedge Funds Weigh In On Immunocore

A number of institutional investors and hedge funds have recently modified their holdings of the stock. RTW Investments LP boosted its holdings in shares of Immunocore by 1.1% in the 3rd quarter. RTW Investments LP now owns 6,096,387 shares of the company’s stock worth $316,402,000 after purchasing an additional 66,754 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Immunocore by 10.2% in the 4th quarter. Wellington Management Group LLP now owns 4,312,611 shares of the company’s stock worth $294,638,000 after purchasing an additional 399,201 shares during the period. FMR LLC boosted its holdings in shares of Immunocore by 4.4% in the 3rd quarter. FMR LLC now owns 2,136,223 shares of the company’s stock worth $110,870,000 after purchasing an additional 90,116 shares during the period. Bellevue Group AG boosted its holdings in shares of Immunocore by 4,817.1% in the 4th quarter. Bellevue Group AG now owns 976,054 shares of the company’s stock worth $66,684,000 after purchasing an additional 956,204 shares during the period. Finally, Braidwell LP boosted its holdings in shares of Immunocore by 93.8% in the 3rd quarter. Braidwell LP now owns 906,973 shares of the company’s stock worth $47,072,000 after purchasing an additional 438,946 shares during the period. Hedge funds and other institutional investors own 84.50% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.